�Fairway Medical Technologies, Inc. has received a $900,000, 3-year contract from the Department of the Navy to apply its optoacoustic engineering science to the real-time spying of blood borne pathogens and biological warfare agents under field conditions. This grant is part of a larger, $3 1000000 project light-emitting diode by Prof. Randolph Glickman, Principal Investigator from the University of Texas Health Science Center (UTHSC) at San Antonio.
The duncan Grant, entitled "Rapid identification of pathogenic agents in biological samples victimisation pulsed optical maser optoacoustic spectrographic analysis with targeted nanoparticle demarcation agents," will be carried out as a collaborative project between UTHSC, Fairway Medical Technologies and the Naval Health Research Center Detachment Directed Energy Bioeffects Laboratory at Brooks City-Base.
"This enquiry is intended to develop a rugged battlefield instrument capable of detecting chemical and biological agents such as anthrax, plague, variola major, and others with the speed, accuracy, sensitivity and reliability of analytical techniques and instruments found in the state of the art laboratory today," said Dr. Glickman.
The optoacoustic biosensor tests samples of blood plasma or other liquids by exploitation monoclonal antibodies (MAB) targeted to specific pathogens. "Elongated gold nanoparticles designed to strongly absorb near-infrared optical maser pulses commode be conjugate to each type of MAB to create a specificity mechanism that will signal the presence of targeted pathogens," explained Dr. Alexander Oraevsky, VP of Research and Development at Fairway and an inventor of this nano-biosensor. "When the nanoparticles produce an acoustic response to laser pulses, the presence and concentration of the pathogens is established." Unique ultrawide-band transducers developed by Fairway for medical imaging and other analytic optoacoustic systems fit the signal acquisition needs of this application, he added.
"This is an crucial continuation of Fairway's stream government and industry-sponsored enquiry. When the R&D part of this project is over, Fairway will manufacture the devices for the Navy and other DoD customers," said Fairway president James Meador.
"Early front detection of biological threats using this kind of rugged field of honor system will provide critical information that can keep Navy sailors and lives of other US military personnel, as well as support quick, well-informed command decision-making," commented Norman Barsalou, project co-investigator from the Navy Bioeffects lab. "We are proud that this collaboration betwixt the UT Health Science Center San Antonio, the Naval Health Research Center Detachment at Brooks and Fairway Medical Technologies pot move this important knead ahead."
About Fairway
Privately held Fairway, which has more than doubled its manufacturing and research capacity in the past 24 months, develops and commercializes products based on proprietorship or licenced technologies, and provides constrict development and manufacturing services for outside clients. A portfolio company of BCM Technologies, the venture working capital subsidiary of Baylor College of Medicine, Fairway has close relationships with to the highest degree of the research institutions located in the Texas Medical Center, and has successfully orchestrated the pattern, development and manufacturing of scores of medical products, including FDA Class III (life encouraging) devices.
Fairway Medical Technologies
More info
